Literature DB >> 32649467

The Relationship Between Lymph Node Ratio and Survival Benefit With Adjuvant Chemotherapy in Node-positive Esophageal Adenocarcinoma.

Vignesh Raman1, Oliver K Jawitz1, Norma E Farrow1, Soraya L Voigt1, Kristen E Rhodin1, Chi-Fu J Yang2, Megan C Turner1, Thomas A D'Amico1, David H Harpole1, Betty C Tong1.   

Abstract

BACKGROUND: We hypothesized that the ratio of positive lymph nodes to total assessed lymph nodes (LNR) is an indicator of cancer burden in esophageal adenocarcinoma and may identify patients who may most benefit from AC.
OBJECTIVE: The aim of this study was to discern whether there is a threshold LNR above which AC is associated with a survival benefit in this population.
METHODS: The 2004-2015 National Cancer Database was queried for patients who underwent upfront, complete resection of pT1-4N1-3M0 esophageal adenocarcinoma. The primary outcome, overall survival, was examined using multivariable Cox proportional hazards models employing an interaction term between LNR and AC.
RESULTS: A total of 1733 patients were included: 811 (47%) did not receive AC whereas 922 (53%) did. The median LNR was 20% (interquartile range 9-40). In a multivariable Cox model, the interaction term between LNR and receipt of AC was significant (P = 0.01). A plot of the interaction demonstrated that AC was associated with improved survival beyond a LNR of about 10%-12%. In a sensitivity analysis, the receipt of AC was not associated with improved survival in patients with LNR <12% (hazard ratio 1.02; 95% confidence interval 0.72-1.44) but was associated with improved survival in those with LNR ≥12% (hazard ratio 0.65; 95% confidence interval 0.50-0.79).
CONCLUSIONS: In this study of patients with upfront, complete resection of node-positive esophageal adenocarcinoma, AC was associated with improved survival for LNR ≥12%. LNR may be used as an adjunct in multidisciplinary decision-making about adjuvant therapies in this patient population.
Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.

Entities:  

Mesh:

Year:  2022        PMID: 32649467      PMCID: PMC7790855          DOI: 10.1097/SLA.0000000000004150

Source DB:  PubMed          Journal:  Ann Surg        ISSN: 0003-4932            Impact factor:   13.787


  26 in total

1.  Lymph Node Ratio as an Alternative to the Number of Metastatic Lymph Nodes for the Prediction of Esophageal Carcinoma Patient Survival.

Authors:  Chen Wei; Wen-Ying Deng; Ning Li; Wei Shen; Chi Zhang; Jia-Yu Liu; Su-Xia Luo
Journal:  Dig Dis Sci       Date:  2015-05-05       Impact factor: 3.199

2.  The positive lymph node ratio predicts long-term survival in patients with operable thoracic esophageal squamous cell carcinoma in China.

Authors:  Xue Hou; Jin-Chang Wei; Ying Xu; Rong-Zhen Luo; Jian-Hua Fu; Lan-Jun Zhang; Peng Lin; Hao-Xian Yang
Journal:  Ann Surg Oncol       Date:  2012-12-18       Impact factor: 5.344

3.  The Lymph Node Ratio Is an Independent Prognostic Factor in Pancreatic Cancer Patients Who Receive Curative Resection Followed by Adjuvant Chemotherapy.

Authors:  Toru Aoyama; Naoto Yamamoto; Mariko Kamiya; Masaaki Murakawa; Hiroshi Tamagawa; Sho Sawazaki; Masakatsu Numata; Manabu Shiozawa; Satoshi Kobayashi; Makoto Ueno; Manabu Morimoto; Norio Yukawa; Takashi Oshima; Takaki Yoshikawa; Yasushi Rino; Munetaka Masuda; Soichiro Morinaga
Journal:  Anticancer Res       Date:  2018-08       Impact factor: 2.480

4.  Disparities in the utilization of high-volume hospitals for complex surgery.

Authors:  Jerome H Liu; David S Zingmond; Marcia L McGory; Nelson F SooHoo; Susan L Ettner; Robert H Brook; Clifford Y Ko
Journal:  JAMA       Date:  2006-10-25       Impact factor: 56.272

5.  Adjuvant chemotherapy following trimodality therapy for esophageal carcinoma-Is the evidence sufficient?

Authors:  Scott M Atay; Mariela Blum; Boris Sepesi
Journal:  J Thorac Dis       Date:  2017-10       Impact factor: 2.895

6.  Prognostic significance of lymph node metastases and ratio in esophageal cancer.

Authors:  Matthew Wilson; Ernest L Rosato; Karen A Chojnacki; Inna Chervoneva; John C Kairys; Herbert E Cohn; Francis E Rosato; Adam C Berger
Journal:  J Surg Res       Date:  2007-08-28       Impact factor: 2.192

7.  The metastatic lymph node number and ratio are independent prognostic factors in esophageal cancer.

Authors:  Wen-Hu Hsu; Po-Kuei Hsu; Chih-Cheng Hsieh; Chien-Sheng Huang; Yu-Chung Wu
Journal:  J Gastrointest Surg       Date:  2009-08-12       Impact factor: 3.452

8.  Prognostic significance of the number of lymph node metastases in esophageal cancer.

Authors:  Alexander J Greenstein; Virginia R Litle; Scott J Swanson; Celia M Divino; Stuart Packer; Juan P Wisnivesky
Journal:  J Am Coll Surg       Date:  2007-11-12       Impact factor: 6.113

9.  Racial disparities in esophageal cancer outcomes.

Authors:  Sha'shonda L Revels; Arden M Morris; Rishindra M Reddy; Clifford Akateh; Sandra L Wong
Journal:  Ann Surg Oncol       Date:  2012-12-23       Impact factor: 5.344

10.  Role of lymph node ratio in selection of adjuvant treatment (chemotherapy vs. chemoradiation) in patients with resected gastric cancer.

Authors:  Brice Jabo; Matthew J Selleck; John W Morgan; Sharon S Lum; Khaled Bahjri; Mayada Aljehani; Carlos A Garberoglio; Mark E Reeves; Jukes P Namm; Naveenraj L Solomon; Fabrizio Luca; Gary Yang; Maheswari Senthil
Journal:  J Gastrointest Oncol       Date:  2018-08
View more
  2 in total

1.  Perioperative CRP: A novel inflammation-based classification in gastric cancer for recurrence and chemotherapy benefit.

Authors:  Jun Lu; Bin-Bin Xu; Zhen Xue; Jian-Wei Xie; Chao-Hui Zheng; Chang-Ming Huang; Ping Li
Journal:  Cancer Med       Date:  2020-12-03       Impact factor: 4.452

2.  The Construction and Validation of Nomogram to Predict the Prognosis with Small-Cell Lung Cancer Followed Surgery.

Authors:  Lei-Lei Wu; Wu-Tao Chen; Chong-Wu Li; Si-Hui Song; Shu-Quan Xu; Sheng-Peng Wan; Zhi-Yuan Liu; Wei-Kang Lin; Kun Li; Zhi-Xin Li; Dong Xie
Journal:  Cancers (Basel)       Date:  2022-07-30       Impact factor: 6.575

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.